Drug Interactions between metoclopramide and Urolene Blue
This report displays the potential drug interactions for the following 2 drugs:
- metoclopramide
- Urolene Blue (methylene blue)
Interactions between your drugs
metoclopramide methylene blue
Applies to: metoclopramide and Urolene Blue (methylene blue)
GENERALLY AVOID: Theoretically, metoclopramide may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Metoclopramide has been shown to induce the release of catecholamines in patients with essential hypertension. This action could produce a synergistic sympathomimetic effect with MAOIs, which enhance norepinephrine storage in adrenergic neurons.
MANAGEMENT: While clinical data are lacking, metoclopramide should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with metoclopramide.
References (2)
- Filibeck DJ, Grimm D, Forman WB, Leidner BA (1984) "Metoclopramide-induced hypertensive crisis." Clin Pharm, 3, p. 548-9
- (2001) "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories
Drug and food interactions
metoclopramide food
Applies to: metoclopramide
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.